Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{5fed0636f5d44de18f221ab9f8efe27c,
title = "The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients",
abstract = "The DBCG89D trial randomized high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil). Prosigna assays were performed by researchers with no access to clinical data. Time to distant recurrence (DR) was the primary endpoint, time to recurrence (TR) and overall survival (OS) secondary. Among the 980 Danish patients enrolled, Prosigna results were obtained in 686. Continuous ROR score was associated with DR for CMF (adjusted hazard ratio (HR) 1.20, 95{\%} CI 1.09-1.33), and for CEF (HR 1.04, 95{\%} CI 0.92-1.18), Pinteraction = 0.06. DR was significantly longer in CEF compared to CMF treated patients with Her2-enriched tumors (HR 0.58, 95{\%} CI 0.38-0.86), but not in patients with luminal tumors. Heterogeneity of treatment effect was significant for TR and OS. In this prospective-retrospective analysis, patients with Her2-enriched breast cancer derived substantial benefit from anthracycline chemotherapy whereas anthracyclines are not an essential component of chemotherapy for patients with luminal subtypes. The benefit of CEF vs. CMF correlated with increasing ROR Score.",
author = "Maj-Britt Jensen and Anne-Vibeke L{\ae}nkholm and Eva Balslev and Wesley Buckingham and Sean Ferree and Vesna Glavicic and {Dupont Jensen}, Jeanette and {S{\o}egaard Knoop}, Ann and Mouridsen, {Henning T} and Dorte Nielsen and Nielsen, {Torsten O} and Bent Ejlertsen",
note = "{\circledC} The Author(s) 2020.",
year = "2020",
doi = "10.1038/s41523-020-0148-0",
language = "English",
volume = "6",
pages = "7",
journal = "Current Medical Literature. Breast Cancer",
issn = "0956-6511",
publisher = "Remedica Medical Education and Publishing Ltd",

}

RIS

TY - JOUR

T1 - The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

AU - Jensen, Maj-Britt

AU - Lænkholm, Anne-Vibeke

AU - Balslev, Eva

AU - Buckingham, Wesley

AU - Ferree, Sean

AU - Glavicic, Vesna

AU - Dupont Jensen, Jeanette

AU - Søegaard Knoop, Ann

AU - Mouridsen, Henning T

AU - Nielsen, Dorte

AU - Nielsen, Torsten O

AU - Ejlertsen, Bent

N1 - © The Author(s) 2020.

PY - 2020

Y1 - 2020

N2 - The DBCG89D trial randomized high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil). Prosigna assays were performed by researchers with no access to clinical data. Time to distant recurrence (DR) was the primary endpoint, time to recurrence (TR) and overall survival (OS) secondary. Among the 980 Danish patients enrolled, Prosigna results were obtained in 686. Continuous ROR score was associated with DR for CMF (adjusted hazard ratio (HR) 1.20, 95% CI 1.09-1.33), and for CEF (HR 1.04, 95% CI 0.92-1.18), Pinteraction = 0.06. DR was significantly longer in CEF compared to CMF treated patients with Her2-enriched tumors (HR 0.58, 95% CI 0.38-0.86), but not in patients with luminal tumors. Heterogeneity of treatment effect was significant for TR and OS. In this prospective-retrospective analysis, patients with Her2-enriched breast cancer derived substantial benefit from anthracycline chemotherapy whereas anthracyclines are not an essential component of chemotherapy for patients with luminal subtypes. The benefit of CEF vs. CMF correlated with increasing ROR Score.

AB - The DBCG89D trial randomized high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil). Prosigna assays were performed by researchers with no access to clinical data. Time to distant recurrence (DR) was the primary endpoint, time to recurrence (TR) and overall survival (OS) secondary. Among the 980 Danish patients enrolled, Prosigna results were obtained in 686. Continuous ROR score was associated with DR for CMF (adjusted hazard ratio (HR) 1.20, 95% CI 1.09-1.33), and for CEF (HR 1.04, 95% CI 0.92-1.18), Pinteraction = 0.06. DR was significantly longer in CEF compared to CMF treated patients with Her2-enriched tumors (HR 0.58, 95% CI 0.38-0.86), but not in patients with luminal tumors. Heterogeneity of treatment effect was significant for TR and OS. In this prospective-retrospective analysis, patients with Her2-enriched breast cancer derived substantial benefit from anthracycline chemotherapy whereas anthracyclines are not an essential component of chemotherapy for patients with luminal subtypes. The benefit of CEF vs. CMF correlated with increasing ROR Score.

U2 - 10.1038/s41523-020-0148-0

DO - 10.1038/s41523-020-0148-0

M3 - Journal article

VL - 6

SP - 7

JO - Current Medical Literature. Breast Cancer

JF - Current Medical Literature. Breast Cancer

SN - 0956-6511

ER -

ID: 60076952